Word: genentech
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...Prilosec and transformed it into a worldwide best seller. At Bristol-Myers Squibb in the late '90s, she worked the same magic on billion-dollar brands like Pravachol (for high cholesterol) and Glucophage (for diabetes). Today Potter, 44, is the COO of the world's No. 2 biotech firm, Genentech, where she's working to bring 20 drugs to market over the next decade. By then, observers believe, Potter stands a good chance of becoming...
...GENE HUNTERS The much hyped biotech industry is finally starting to deliver on its promise, with more small companies shifting from basic research to drug development. That means more jobs, from lab work to medical writing, are in the pipeline as well. Genentech, based in South San Francisco, Calif., is increasing its head count each year by 297, or about 6% annually, hiring everyone from Ph.D.s to community-college grads who can work in manufacturing. Just in the budding field of bioinformatics, in which specialists can make more than $100,000 a year using computers to plow through reams...
...postdoctoral fellow at the University of California in San Francisco in the 1970s, and later at Genentech, Ullrich worked on cloning the gene for insulin. His research led to the development of the first commercial medical treatment, human insulin for diabetes, produced through recombinant dna technology. Since then Ullrich has been on a quest to battle cancer by concentrating on signal transduction, a means of communication between cells in the human body. From this work came the drug Herceptin, the first treatment to aim at the cells that cause breast cancer. Ullrich's approach is not to target the cancer...
Consider the plight of biotech firm Genentech in the early '90s. It had four promising drugs that it wanted to take into clinical trials one year, but it had resources for only three. On the bubble: the breast-cancer drug Herceptin. The R.-and-D. tax credit provided funds for Genentech to proceed with that fourth drug, which came to market last year and is now saving lives while ringing up sales of $75 million a quarter. With the tax credit, says Walter Moore, vice president of government affairs at Genentech, his company is able to pursue one additional drug...
Sources: Good News: Journal of the American Medical Association (5/2/00), FDA; Bad News: Annals of Internal Medicine (5/2/00), Genentech...